Moleculera Labs, Inc.
A neuroimmunology diagnostics company focused on changing how medicine is practiced for neuropsychiatric and behavioral disorders
Over 60MM Americans suffer from neuropsychiatric and developmental disorders and are treated with neuropsychiatric drugs, often with little improvement. We identify patients whose symptoms are triggered by an immune dysfunction. When properly diagnosed and treated they have remarkable recoveries. Disorders include PANDAS/PANS, ADD/ADHD, autism, anxiety disorder, OCD and others. We generated over $5.5MM in cumulative revenue on a $5MM investment.